Altimmune Prepares FDA Phase 3 AUD Talks After Pemvidutide Cut Heavy-Drinking Days By 4.2 Per Week

Altimmune is heading into FDA discussions next month on a registrational program for pemvidutide in alcohol use disorder after posting mid-stage data that showed the glucagon/GLP-1 dual receptor agonist reduced heavy drinking versus placebo. The company revisited the RECLAIM results at the American Association for the Study of Liver Diseases meeting in Denver after first sharing topline data in July.

The strategic shift now is from signal finding to execution. Alcohol use disorder has attracted increasing interest from metabolic drug developers, but running a late-stage program can be expensive, and Altimmune is moving forward while also funding a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.

The data

Investigators randomized about 100 people with alcohol use disorder to receive pemvidutide or placebo once weekly for 24 weeks, together with a standardized behavioral intervention. The trial met its primary endpoint.

Compared with baseline, patients on pemvidutide had 4.2 fewer heavy-drinking days per week during weeks 21 to 24 of the study. Patients on placebo had 2.75 fewer heavy-drinking days per week. Altimmune said in July that the result was highly statistically significant.

William Blair highlighted a 38% reduction in serum phosphatidylethanol, a direct biomarker for alcohol consumption, versus a 5.9% increase with placebo. The firm described that biomarker result as the strongest validation for pemvidutide in the indication.

The same analysts said that, noting the limitations of cross-trial comparisons, pemvidutide appears to show a more robust clinical profile than short-duration low-dose semaglutide. The source pointed to a Phase 2 trial in February 2025 in which weekly heavy-drinking days fell from two to less than one in 48 patients who took semaglutide for nine weeks.

What comes next

Altimmune has scheduled an end-of-Phase 2 meeting with the FDA for next month to discuss the design of a Phase 3 registrational program in alcohol use disorder. That meeting is the clearest near-term inflection point because it should define how much development work, duration and capital the company may need before a filing path comes into view.

Competition is already scaling up. Last year, Eli Lilly started two Phase 3 trials of brenipatide in adults with alcohol use disorder. Each study was designed to enroll 1,100 patients and assess whether taking the GLP-1/GIP receptor agonist for 56 weeks changes drinking patterns, with the trials scheduled to wrap in early 2028, according to the federal trial database.

William Blair said Altimmune will require additional capital to fund a pivotal program in alcohol use disorder, citing the size and duration of Lilly’s studies. Altimmune ended June with $519 million in cash, cash equivalents and investments.

That cash position gives the company room to reach the FDA meeting from a position of relative strength, but the broader signal is that encouraging Phase 2 alcohol use disorder data may not be enough on its own. For Altimmune, the value of pemvidutide in this indication will depend on whether it can translate a differentiated mid-stage dataset into a late-stage plan that investors believe is financeable alongside its MASH program.